{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:08:30Z","timestamp":1789952910330,"version":"4.0.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SCHBUL"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1093\/schbul\/sbv072","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T21:22:09Z","timestamp":1434144129000},"page":"335-343","source":"Crossref","is-referenced-by-count":89,"title":["Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia"],"prefix":"10.1093","volume":"42","author":[{"given":"David","family":"Walling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Wolfgang","family":"Fleischhacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S. E.","family":"Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Hosford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Dvergsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Segreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.","family":"Beaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Toler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Jett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey C.","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,6,12]]},"reference":[{"key":"2016021519341831000_42.2.335.1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, Virginia: APA; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2016021519341831000_42.2.335.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2004.09.010"},{"key":"2016021519341831000_42.2.335.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2004.09.008"},{"key":"2016021519341831000_42.2.335.4","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbj055"},{"key":"2016021519341831000_42.2.335.5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2006.00947.x","article-title":"Negative symptoms of schizophrenia: a problem that will not go away","volume":"115","author":"Stahl","year":"2007","journal-title":"Acta Psychiatr Scand"},{"key":"2016021519341831000_42.2.335.6","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e32835d8296"},{"key":"2016021519341831000_42.2.335.7","first-page":"18","article-title":"Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia","volume":"18","author":"Addington","year":"1993","journal-title":"J Psychiatry Neurosci"},{"key":"2016021519341831000_42.2.335.8","doi-asserted-by":"publisher","DOI":"10.1192\/apt.6.3.161"},{"key":"2016021519341831000_42.2.335.9","first-page":"12","article-title":"Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction","volume":"26","author":"Fleischhacker","year":"2000","journal-title":"Encephale"},{"key":"2016021519341831000_42.2.335.10","first-page":"263","article-title":"Course of cognitive symptoms in schizophrenia: a review of the literature","volume":"35","author":"Ojeda","year":"2007","journal-title":"Actas Esp Psiquiatr"},{"key":"2016021519341831000_42.2.335.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.03.005"},{"key":"2016021519341831000_42.2.335.12","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.09040574"},{"key":"2016021519341831000_42.2.335.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2012.01.035"},{"key":"2016021519341831000_42.2.335.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2004.09.007"},{"key":"2016021519341831000_42.2.335.15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07010042"},{"key":"2016021519341831000_42.2.335.16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07010043"},{"key":"2016021519341831000_42.2.335.17","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbm074"},{"key":"2016021519341831000_42.2.335.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.07.015"},{"key":"2016021519341831000_42.2.335.19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2007.07101596"},{"key":"2016021519341831000_42.2.335.20","doi-asserted-by":"publisher","DOI":"10.2174\/138920111794480589"},{"key":"2016021519341831000_42.2.335.21","doi-asserted-by":"crossref","unstructured":"Blanchard JJ Kring AM Horan WP Gur R . Toward the next generation of negative symptom assessments: the collaboration to advance negative symptoms assessment of schizophrenia. Schizophr Bull. 2011;37:291\u2013299.","DOI":"10.1093\/schbul\/sbq104"},{"key":"2016021519341831000_42.2.335.22","doi-asserted-by":"crossref","unstructured":"Marder SR Daniel DG Alphs L Awad AG Keefe RSE . Methodological issues in negative symptom trials. Schizophr Bull. 2011;37:250\u2013254.","DOI":"10.1093\/schbul\/sbq161"},{"key":"2016021519341831000_42.2.335.23","doi-asserted-by":"crossref","unstructured":"Laughren T Levin R . Food and Drug Administration commentary on methodological issues in negative symptom trials. Schizophr Bull. 2011;37:255\u2013256.","DOI":"10.1093\/schbul\/sbq162"},{"key":"2016021519341831000_42.2.335.24","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(92)91437-J"},{"key":"2016021519341831000_42.2.335.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.2.587"},{"key":"2016021519341831000_42.2.335.26","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(94)00252-X"},{"key":"2016021519341831000_42.2.335.27","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0731590.x"},{"key":"2016021519341831000_42.2.335.28","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.6.630"},{"key":"2016021519341831000_42.2.335.29","unstructured":"EnVivo Pharmaceuticals, EnVivo reports positive results of its EVP-6124 clinical biomarker study in schizophrenia patients. 2009."},{"key":"2016021519341831000_42.2.335.30","unstructured":"EnVivo Pharmaceuticals, EnVivo announces positive phase 2b clinical data in schizophrenia: EVP 6124 meets primary endpoint with statistically significant improvements in cognition and multiple secondary endpoints for improvement in function and impact on negative symptoms. 2011."},{"key":"2016021519341831000_42.2.335.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.05.030"},{"key":"2016021519341831000_42.2.335.32","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.259"},{"key":"2016021519341831000_42.2.335.33","doi-asserted-by":"crossref","unstructured":"Helsinki. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Seoul, Korea: 59th WMA General Assembly; 2008.","DOI":"10.1515\/9783110208856.233"},{"key":"2016021519341831000_42.2.335.34","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.64.10.1123"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/42\/2\/335\/7681609\/sbv072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T17:32:45Z","timestamp":1566840765000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-lookup\/doi\/10.1093\/schbul\/sbv072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,12]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,14]]},"published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1093\/schbul\/sbv072"],"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbv072","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,12]]}}}